2003
DOI: 10.1378/chest.123.3.956
|View full text |Cite
|
Sign up to set email alerts
|

Pericardiocentesis and Pancreatic Aspiration Needle Biopsy in Coagulopathic and Thrombocytopenic Cirrhotic Patienta

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
4
0

Year Published

2004
2004
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 9 publications
(4 citation statements)
references
References 8 publications
0
4
0
Order By: Relevance
“…The half-life is approximately 2 hours, and the effects can be seen within 3 to 4 hours; this is dependent on the dose administered. Therapy with rFVIIa prevented bleeding in patients with liver disease undergoing liver biopsy [29] and other invasive procedures, such as injection of hepatocellular carcinoma, colonoscopic polypectomy, intracranial pressure monitor placement, pericardiocentesis, or pancreatic aspiration [26,[30][31][32]. Therapy with rFVIIa prevented bleeding in patients with liver disease undergoing liver biopsy [29] and other invasive procedures, such as injection of hepatocellular carcinoma, colonoscopic polypectomy, intracranial pressure monitor placement, pericardiocentesis, or pancreatic aspiration [26,[30][31][32].…”
Section: Recombinant Activated Factor VII (Rfviia)mentioning
confidence: 99%
“…The half-life is approximately 2 hours, and the effects can be seen within 3 to 4 hours; this is dependent on the dose administered. Therapy with rFVIIa prevented bleeding in patients with liver disease undergoing liver biopsy [29] and other invasive procedures, such as injection of hepatocellular carcinoma, colonoscopic polypectomy, intracranial pressure monitor placement, pericardiocentesis, or pancreatic aspiration [26,[30][31][32]. Therapy with rFVIIa prevented bleeding in patients with liver disease undergoing liver biopsy [29] and other invasive procedures, such as injection of hepatocellular carcinoma, colonoscopic polypectomy, intracranial pressure monitor placement, pericardiocentesis, or pancreatic aspiration [26,[30][31][32].…”
Section: Recombinant Activated Factor VII (Rfviia)mentioning
confidence: 99%
“…However, there are not enough clinical data regarding the safety of pericardiocentesis in patients under antiplatelet or anticoagulant drugs. Several cases have reported its feasibility in patients with uncorrected coagulopathy, such as thrombocytopenia or elevated INR due to cancer, chemotherapy, and cirrhosis ( 18 20 ). Iliescu et al ( 21 ) analyzed cancer patients presenting with cardiac tamponade in the setting of thrombocytopenia and identified 2 major bleeding events out of 60 procedures.…”
Section: Discussionmentioning
confidence: 99%
“…However, literature data regarding the feasibility of pericardiocentesis in patients with uncorrected bleeding diathesis are limited. There are only several case reports all of which demonstrated that pericardiocentesis is safe and effective in subjects with thrombocytopenia [3][4][5][6]. Moreover to our knowledge, pericardiocentesis in the setting of both thrombocytopenia and high INR has not been reported previously.…”
mentioning
confidence: 82%